Written by Holly Alyssa MacCormick Cory R. Nicholas presenting at the January 29 ICOC board meeting About 3 million adults in the United States have epilepsy, including roughly 400,000 in California, according to the CDC. About one-third to one-half continue to have seizures that do not respond to available medications. Hope for those with epilepsy … Continue reading Cory R. Nicholas shares update on epilepsy clinical trials
Epilepsy
Neurona Doses First Patient in CIRM-Funded Bilateral Epilepsy Cell Therapy Trial
Image Credit: Canva Stock Photo Neurona Therapeutics has reached a major milestone in the development of its stem cell approach to treating epilepsy. A new phase in clinical trial The company recently announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating NRTX-1001, a cell therapy for adults whose epilepsy … Continue reading Neurona Doses First Patient in CIRM-Funded Bilateral Epilepsy Cell Therapy Trial
A patient’s journey with an epilepsy stem cell therapy
Justin Graves diving by the Grand Cayman Islands In 2007, Justin Graves was working at a SCUBA shop in Louisville, Kentucky, when he had his first epileptic seizure. "SCUBA diving has just been something I've loved my whole life," he said. "My whole family loves it." Medication not always effective Justin had to give up … Continue reading A patient’s journey with an epilepsy stem cell therapy
A Conversation with CEO Cory Nicholas on Neurona Therapeutics’ Recent RMAT Designation
At the California Institute for Regenerative Medicine (CIRM), we highlight achievements from the research we support. We recently spoke with Cory Nicholas, PhD, CEO and Co‑Founder of Neurona Therapeutics, about a major milestone for the clinical‑stage company. Neurona received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for NRTX‑1001, a CIRM‑funded neural cell therapy for … Continue reading A Conversation with CEO Cory Nicholas on Neurona Therapeutics’ Recent RMAT Designation
First, epilepsy patients who received treatment experienced fewer seizures
Nearly 3.5 million Americans live with epilepsy. Symptoms vary widely, from stiff muscles or staring spells to violent shaking and loss of consciousness. The condition’s impact extends far beyond seizures. People with epilepsy face higher rates of depression, social isolation, school and employment challenges, limits on driving, and increased risk of early death. Medication helps … Continue reading First, epilepsy patients who received treatment experienced fewer seizures
So far, some encouraging news for a clinical trial treating epilepsy
Neurona Therapeutics is testing a new therapy for a drug-resistant form of epilepsy and has just released some encouraging early findings. The first patient treated went from having more than 30 seizures a month to just four seizures over a three-month period. CIRM-supported trial This clinical trial, funded by the California Institute for Regenerative Medicine … Continue reading So far, some encouraging news for a clinical trial treating epilepsy
First patient dosed in a clinical trial for a drug-resistant epilepsy
Tablet BM47753. Neo-Babylonian Period. Courtesy of the British Museum, London. Epilepsy has challenged people for as long as we have recorded history. A 4,000‑year‑old Akkadian tablet from Mesopotamia describes a person with stiff muscles, wide eyes, frothing at the mouth, and no awareness—an early description of a seizure. Early treatments Despite this long history, effective … Continue reading First patient dosed in a clinical trial for a drug-resistant epilepsy
The long road to developing a therapy for epilepsy
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Good science takes time. That’s an essential guiding principle for researchers, but a frustrating reality for patients who need help now. CIRM-funded epilepsy research That point was clear when the CIRM Board voted to invest nearly $8 million to test a new approach for drug‑resistant epilepsy. … Continue reading The long road to developing a therapy for epilepsy
Promising new approach to treat epilepsy
Image courtesy of Epilepsy.com A new therapeutic approach, supported by CIRM, that blocks brain signals that can cause epilepsy has been approved by the US Food and Drug Administration (FDA) for clinical trials. More on epilepsy Nearly 3.5 million Americans suffer from some form of epilepsy. It can affect people in different ways, from stiff … Continue reading Promising new approach to treat epilepsy
You can bank on CIRM
Way back in 2013, the CIRM Board invested $32 million in a project to create an iPSC Bank. The goal was simple; to collect tissue samples from people who have different diseases, turn those samples into high quality stem cell lines - the kind known as induced pluripotent stem cells (iPSC) - and create a … Continue reading You can bank on CIRM